Inception Growth Acquisition Ltd (IGTAW)

Inception Growth Acquisition Ltd issues IGTAW warrants — equity options that give holders the right to purchase additional common shares at a pre-set price after a merger closes. A warrant is a leveraged bet: you pay a fraction of the cost of owning the stock outright, but you gain full upside above the exercise price, with no downside floor, no redemption right, and nothing if the SPAC fails to merge or the merged company’s stock falls below the strike.

Ticker	IGTAW (NASDAQ)
Security type	SPAC warrant / equity call option
Typical exercise price	$11.50 per share of common stock
Exercise window	Post-merger; usually 5 years or until expiration
Leverage	No floor; full downside risk if stock declines
No redemption right	Unlike common shares; warrant holders cannot exit at cost
SEC CIK	0001866838

How a warrant works

When you buy a warrant, you own the right but not the obligation to buy one common share at $11.50 per share at any time before the warrant expires (usually five years post-merger). If the merged company’s stock trades at $20, the warrant is in the money by $8.50 and has intrinsic value. If the stock trades at $8, the warrant is worthless and exercises to no effect. You lose your entire warrant premium; the sponsor or the company does not reimburse you.

This is the opposite of a redemption right. Common shareholders can exit a disappointing SPAC merger by redeeming and recovering their share of the trust. Warrant holders must hold or sell; they are stuck with the bet. That asymmetry is why warrants are risky, why they trade at a discount to their mathematical value most of the time (factoring in time decay and the probability of the stock trading above strike), and why retail investors often overestimate how much value they contain.

Price dynamics: pre and post merger

Before the merger closes, IGTAW trades in separation from the common stock. The common typically trades near or slightly below the trust value (because redemptions compress it), while the warrant trades on speculation about the target. If the target looks solid, the warrant may soar to $2, $3, or higher, capitalizing on the prospect that the merged stock will trade well above $11.50. If the target disappoints, the warrant collapses. The spread between warrant price and intrinsic value is pure optionality — time value, the market’s estimate of how likely the stock is to finish in the money.

Post-merger, the warrant trades alongside the common. If the merged company’s stock rallies and the warrant is deep in the money, warrant holders exercise, converting their $11.50 strike into real shares at a bargain. But many warrants simply expire worthless. A 2023 study of SPACs that completed mergers found that roughly 70% of warrants expired out of the money, generating nothing for their original holders.

Sponsors retain founder shares that vest only if the stock hits defined hurdles post-merger (often $12 per share by a certain date, then escalating). Because founder shares are free to the sponsor, their motivation is to see the stock rally hard and fast — and the warrant overhang (the potential dilution if many warrants exercise) can be a material headwind on that rally. Every warrant exercised adds a new share, reducing existing shareholders’ ownership and potentially suppressing the stock price. This creates a tension: the SPAC sponsor wants the stock to run, but the warrant-induced dilution works against it. Sophisticated investors factor this in, and it is one reason warrant value often disappoints.

The fine print that matters

The exercise terms matter enormously. Some SPACs have “call provisions” that allow the company to force early exercise if the stock trades well above $18 for a sustained period, a feature designed to eliminate the warrant overhang. Others allow cash settlement — the company can pay the warrant holder $11.50 per warrant in lieu of allowing exercise. Still others have no such levers and the warrants simply linger, diluting the capitalization.

The expiration date is also critical. A SPAC warrant that expires in five years provides years of optionality; one that expires sooner is more prone to time decay. Some newer SPACs have experimented with warrants that auto-convert to common shares at a ratio if not exercised by the deadline, a move designed to simplify the capital structure but often favorable to the company and unfavorable to the warrant holder.

Understanding value in the filings

The merger proxy details the warrant terms: the strike price, the exercise window, any call provisions, and the number outstanding. The prospectus filed at the IPO also specifies these. For a SPAC like Inception Growth, anyone considering the warrants should compare the strike price to the target company’s valuation, asking: what do I need to believe about this company’s stock performance for the warrant to be worth exercising? A $11.50 strike on a company with modest growth projections is a speculative bet that the market will overpay for the stock post-merger — possible, but increasingly rare.